NASDAQ:VRTX - Vertex Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $264.44
  • Forecasted Upside: 31.89 %
  • Number of Analysts: 23
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 17 Buy Ratings
  • 0 Strong Buy Ratings
▲ +4.48 (2.29%)

This chart shows the closing price for VRTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vertex Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRTX

Analyst Price Target is $264.44
▲ +31.89% Upside Potential
This price target is based on 23 analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $264.44, with a high forecast of $331.00 and a low forecast of $170.00. The average price target represents a 31.89% upside from the last price of $200.50.

This chart shows the closing price for VRTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 23 polled investment analysts is to buy stock in Vertex Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 20 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 24 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 24 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 24 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 25 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 21 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 19 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 17 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 17 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/20/2021SVB LeerinkDowngradeMarket Perform ➝ Underperform$200.00 ➝ $170.00Low
7/19/2021Wolfe ResearchInitiated CoverageOutperform$252.00Low
6/30/2021Raymond JamesInitiated CoverageMarket PerformLow
6/14/2021TruistBoost Price TargetBuy$305.00 ➝ $331.00Low
6/14/2021Piper SandlerLower Price TargetOverweight$347.00 ➝ $261.00Low
6/14/2021Truist SecuritiesBoost Price TargetBuy$305.00 ➝ $331.00Low
6/14/2021SVB LeerinkLower Price TargetReduce ➝ Market Perform$250.00 ➝ $200.00Low
6/13/2021Evercore ISIReiterated RatingBuyLow
6/11/2021Stifel NicolausLower Price TargetBuy$277.00 ➝ $244.00High
6/11/2021The Goldman Sachs GroupLower Price TargetBuy$358.00 ➝ $307.00High
6/11/2021BarclaysLower Price TargetOverweight$302.00 ➝ $285.00High
6/11/2021Cantor FitzgeraldLower Price TargetOverweight$285.00 ➝ $281.00High
6/11/2021Morgan StanleyLower Price TargetEqual Weight$254.00 ➝ $205.00High
6/11/2021Robert W. BairdLower Price TargetOutperform$252.00 ➝ $240.00High
6/11/2021Royal Bank of CanadaLower Price TargetPositive ➝ Outperform$262.00 ➝ $242.00High
6/11/2021Daiwa Capital MarketsDowngradeOutperform ➝ Neutral$210.00High
5/3/2021Morgan StanleyBoost Price TargetEqual Weight$253.00 ➝ $254.00Low
4/26/2021Morgan StanleyBoost Price TargetEqual Weight$253.00 ➝ $254.00N/A
4/19/2021Morgan StanleyBoost Price TargetEqual Weight$251.00 ➝ $253.00Low
4/11/2021Royal Bank of CanadaReiterated RatingBuyLow
2/23/2021Robert W. BairdUpgradeNeutral ➝ Outperform$220.00 ➝ $252.00Medium
2/2/2021BMO Capital MarketsLower Price TargetOutperform$302.00 ➝ $284.00Low
2/2/2021Credit Suisse GroupLower Price TargetOutperform$285.00 ➝ $280.00Low
2/2/2021SVB LeerinkLower Price TargetMarket Perform$257.00 ➝ $250.00Low
2/2/2021Piper SandlerBoost Price TargetOverweight$307.00 ➝ $347.00Low
2/2/2021HC WainwrightLower Price TargetBuy$315.00 ➝ $275.00Low
1/19/2021Morgan StanleyBoost Price TargetEqual Weight$249.00 ➝ $251.00Low
12/30/2020Daiwa Capital MarketsInitiated CoverageOutperform$250.00N/A
12/11/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
11/30/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$247.00 ➝ $267.00Low
11/20/2020Sanford C. BernsteinInitiated CoverageOutperform$275.00Low
11/1/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
10/30/2020Piper SandlerLower Price TargetOverweight$327.00 ➝ $307.00Low
10/30/2020Credit Suisse GroupLower Price TargetOutperform$292.00 ➝ $285.00Low
10/30/2020SVB LeerinkLower Price TargetMarket Perform$267.00 ➝ $257.00High
10/28/2020UBS GroupInitiated CoverageBuy$287.00Low
10/26/2020Needham & Company LLCReiterated RatingHoldMedium
10/19/2020Morgan StanleyLower Price TargetEqual Weight$281.00 ➝ $249.00Medium
10/15/2020TruistLower Price Target$330.00 ➝ $305.00High
10/15/2020SVB LeerinkLower Price TargetMarket Perform$283.00 ➝ $267.00High
10/13/2020Morgan StanleyLower Price TargetEqual Weight$300.00 ➝ $281.00Low
9/18/2020Maxim GroupReiterated RatingHoldHigh
8/24/2020SVB LeerinkBoost Price TargetNeutral ➝ Market Perform$274.00 ➝ $283.00Medium
7/31/2020Cantor FitzgeraldBoost Price TargetOverweight$293.00 ➝ $305.00High
7/31/2020SVB LeerinkBoost Price TargetMarket Perform$263.00 ➝ $274.00High
7/31/2020HC WainwrightReiterated RatingBuy$295.00 ➝ $315.00High
7/31/2020Piper SandlerBoost Price TargetOverweight$302.00 ➝ $327.00High
7/20/2020Credit Suisse GroupBoost Price TargetOutperform$298.00 ➝ $328.00High
7/16/2020CowenBoost Price TargetOutperform$265.00 ➝ $300.00Low
7/14/2020Jefferies Financial GroupBoost Price TargetBuy$295.00 ➝ $340.00High
7/8/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$277.00 ➝ $300.00Medium
7/2/2020The Goldman Sachs GroupBoost Price TargetPositive ➝ Conviction-Buy$290.00 ➝ $330.00Low
6/24/2020SunTrust BanksBoost Price TargetBuy$285.00 ➝ $330.00High
6/12/2020CitigroupBoost Price TargetTop Pick ➝ Buy$305.00 ➝ $325.00Low
5/15/2020ArgusBoost Price TargetBuy$270.00 ➝ $320.00High
5/1/2020CitigroupBoost Price TargetBuy$265.00 ➝ $305.00Medium
4/30/2020Credit Suisse GroupReiterated RatingBuy$298.00Medium
4/30/2020CfraBoost Price TargetBuy$286.00 ➝ $297.00Low
4/30/2020GuggenheimBoost Price TargetBuy$266.00 ➝ $290.00High
4/30/2020BMO Capital MarketsBoost Price TargetOutperform$279.00 ➝ $283.00High
4/30/2020Stifel NicolausBoost Price TargetBuy$275.00 ➝ $285.00High
4/30/2020OppenheimerBoost Price TargetOutperform$265.00 ➝ $305.00High
4/30/2020Morgan StanleyBoost Price TargetOverweight$258.00 ➝ $277.00High
4/30/2020SVB LeerinkBoost Price TargetMarket Perform$224.00 ➝ $263.00High
4/30/2020JMP SecuritiesBoost Price TargetMarket Outperform$255.00 ➝ $285.00High
4/30/2020HC WainwrightBoost Price TargetBuy$270.00 ➝ $295.00High
4/28/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$250.00 ➝ $260.00High
4/27/2020Piper SandlerReiterated RatingBuy$300.00High
4/15/2020Morgan StanleyBoost Price TargetOverweight$251.00 ➝ $258.00Medium
3/27/2020Piper SandlerReiterated RatingBuy$300.00High
3/12/2020Wolfe ResearchInitiated CoverageOutperform$282.00High
3/11/2020Cantor FitzgeraldReiterated RatingOverweight$262.00 ➝ $275.00Medium
3/4/2020BarclaysInitiated CoverageOverweight$271.00High
3/3/2020CowenReiterated RatingBuy$260.00Medium
3/2/2020ArgusBoost Price TargetPositive ➝ Buy$248.00 ➝ $270.00High
2/2/2020Evercore ISIReiterated RatingHold$270.00Medium
1/31/2020Piper SandlerBoost Price Target$284.00 ➝ $300.00Medium
1/31/2020Bank of AmericaReiterated RatingBuy$250.00 ➝ $295.00High
1/31/2020Needham & Company LLCReiterated RatingHoldHigh
1/31/2020Morgan StanleyBoost Price TargetOverweight$250.00 ➝ $251.00Low
1/31/2020Stifel NicolausBoost Price TargetBuy$243.00 ➝ $275.00High
1/31/2020Royal Bank of CanadaBoost Price TargetOutperform$240.00 ➝ $260.00High
1/31/2020CfraBoost Price TargetBuy$237.00 ➝ $286.00High
1/31/2020Credit Suisse GroupBoost Price TargetOutperform$253.00 ➝ $258.00High
1/31/2020SunTrust BanksReiterated RatingBuy$285.00High
1/31/2020JPMorgan Chase & Co.Boost Price TargetOverweight$247.00 ➝ $260.00High
1/31/2020HC WainwrightBoost Price TargetBuy$220.00 ➝ $270.00High
1/31/2020Robert W. BairdDowngradeOutperform ➝ Neutral$210.00 ➝ $230.00High
1/14/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
1/9/2020BMO Capital MarketsBoost Price Target$248.00 ➝ $268.00Low
1/8/2020OppenheimerBoost Price TargetOutperform$230.00 ➝ $265.00Low
1/6/2020Piper Jaffray CompaniesBoost Price TargetOverweight$247.00 ➝ $284.00N/A
1/2/2020Raymond JamesDowngradeOutperform ➝ Market PerformLow
12/18/2019JPMorgan Chase & Co.Boost Price TargetOverweight$218.00 ➝ $247.00Low
12/16/2019ArgusBoost Price TargetBuy$248.00Medium
12/13/2019Credit Suisse GroupUpgradeBuy$231.00Low
11/20/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Positive$248.00Low
11/19/2019CowenReiterated RatingBuyLow
11/19/2019GuggenheimUpgradeNeutral ➝ Buy$252.00High
11/12/2019SunTrust BanksInitiated CoverageBuy$235.00Medium
11/4/2019Credit Suisse GroupReiterated RatingBuy$228.00Low
11/1/2019Maxim GroupReiterated RatingHoldHigh
10/31/2019Piper Jaffray CompaniesBoost Price TargetOverweight$230.00 ➝ $247.00High
10/22/2019Credit Suisse GroupBoost Price TargetOverweight$213.00 ➝ $221.00Low
10/22/2019SVB LeerinkBoost Price TargetMarket Perform$186.00 ➝ $203.00High
10/22/2019CitigroupBoost Price TargetBuy$205.00 ➝ $225.00High
10/21/2019BMO Capital MarketsSet Price TargetBuy$232.00Medium
10/21/2019Jefferies Financial GroupSet Price TargetBuy$220.00Medium
10/21/2019CowenSet Price TargetBuy$220.00Medium
10/21/2019Robert W. BairdSet Price TargetBuy$210.00Medium
10/21/2019JPMorgan Chase & Co.Set Price TargetBuy$218.00Medium
10/16/2019Bank of AmericaInitiated CoverageBuy$220.00Medium
9/23/2019Jefferies Financial GroupBoost Price Target$210.00 ➝ $220.00Medium
9/6/2019Morgan StanleyBoost Price TargetOverweight$215.00 ➝ $240.00Low
9/3/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$226.00 ➝ $254.00High
8/12/2019Royal Bank of CanadaSet Price TargetBuy$213.00Low
8/2/2019Maxim GroupReiterated RatingHoldLow
8/1/2019Credit Suisse GroupBoost Price TargetOutperform$209.00 ➝ $213.00Low
8/1/2019Piper Jaffray CompaniesBoost Price TargetOverweight$217.00 ➝ $230.00Low
8/1/2019Stifel NicolausBoost Price TargetBuy$205.00 ➝ $211.00Low
8/1/2019JPMorgan Chase & Co.Reiterated RatingBuy$212.00High
8/1/2019HC WainwrightReiterated RatingBuy$220.00High
8/1/2019Needham & Company LLCDowngradeBuy ➝ HoldHigh
7/31/2019CowenSet Price TargetBuy$220.00N/A
6/2/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
5/23/2019The Goldman Sachs GroupReiterated RatingBuy$220.00Low
5/23/2019CitigroupReiterated RatingBuy ➝ Buy$205.00Low
5/20/2019Credit Suisse GroupInitiated CoverageOutperform$209.00 ➝ $209.00Medium
5/1/2019Needham & Company LLCReiterated RatingBuy$195.00Low
5/1/2019JPMorgan Chase & Co.Reiterated RatingBuy$209.00High
4/30/2019CowenReiterated RatingBuy$220.00High
4/11/2019Evercore ISIInitiated CoverageIn-Line$183.00Low
3/26/2019William BlairUpgradeMarket Perform ➝ Outperform$183.85Medium
3/19/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$185.40Medium
3/7/2019OppenheimerBoost Price TargetOutperform ➝ Outperform$200.00 ➝ $230.00Low
3/6/2019CowenReiterated RatingBuy$220.00Medium
3/6/2019Maxim GroupReiterated RatingHoldMedium
2/6/2019BMO Capital MarketsBoost Price TargetOutperform$234.00High
2/6/2019Maxim GroupDowngradeBuy ➝ HoldHigh
1/4/2019CitigroupLower Price TargetBuy ➝ Buy$206.00 ➝ $205.00Medium
1/2/2019Raymond JamesDowngradeOutperform ➝ Market Perform$165.71Low
12/19/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$211.00 ➝ $210.00High
12/17/2018GuggenheimInitiated CoverageNeutralMedium
12/17/2018Cantor FitzgeraldReiterated RatingBuy$217.00High
11/27/2018OppenheimerSet Price TargetBuy$200.00High
11/27/2018Cantor FitzgeraldReiterated RatingBuy$217.00Low
10/26/2018Piper Jaffray CompaniesLower Price TargetOverweight$217.00Medium
10/26/2018HC WainwrightUpgradeNeutral ➝ Buy$220.00High
10/25/2018BMO Capital MarketsLower Price TargetOutperform$204.00 ➝ $192.00High
10/25/2018Raymond JamesSet Price TargetBuy$211.00 ➝ $201.00High
10/24/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
10/2/2018Raymond JamesInitiated CoverageBuyLow
10/1/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$217.00Medium
8/28/2018ArgusBoost Price TargetBuy ➝ Average$200.00High
8/7/2018Stifel NicolausBoost Price TargetBuy$182.00 ➝ $200.00Medium
7/30/2018CitigroupBoost Price TargetBuy ➝ Buy$203.00 ➝ $206.00Medium
7/26/2018Royal Bank of CanadaReiterated RatingBuy$203.00Medium
7/26/2018UBS GroupBoost Price TargetNeutral ➝ Neutral$183.00 ➝ $188.00High
7/26/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$207.00 ➝ $211.00High
7/26/2018OppenheimerBoost Price TargetOutperform$180.00 ➝ $200.00High
7/26/2018Piper Jaffray CompaniesBoost Price TargetOverweight$230.00High
7/26/2018BMO Capital MarketsBoost Price TargetOutperform$204.00High
7/16/2018Jefferies Financial GroupBoost Price TargetBuy$210.00Low
7/1/2018JPMorgan Chase & Co.Reiterated RatingBuyLow
6/12/2018ArgusSet Price TargetBuy ➝ Buy$172.00Low
4/27/2018CowenReiterated RatingBuy$200.00Low
4/27/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$200.00 ➝ $207.00Low
4/27/2018Maxim GroupReiterated RatingBuy$200.00High
3/5/2018Maxim GroupBoost Price TargetBuy ➝ Buy$195.00 ➝ $200.00Medium
2/23/2018ArgusSet Price TargetBuy ➝ Buy$194.00High
2/13/2018JMP SecuritiesReiterated RatingMarket Outperform ➝ Outperform$200.00 ➝ $211.00Low
2/13/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$195.00 ➝ $196.00Low
2/13/2018HC WainwrightReiterated RatingHold$103.00Low
2/2/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$198.00 ➝ $200.00Medium
2/1/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$180.00 ➝ $197.00High
2/1/2018HC WainwrightReiterated RatingHold$103.00High
2/1/2018CitigroupReiterated RatingBuyHigh
2/1/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Buy$184.00 ➝ $191.00High
2/1/2018SVB LeerinkReiterated RatingOutperform$175.00 ➝ $190.00High
2/1/2018Royal Bank of CanadaBoost Price TargetOutperform$200.00High
2/1/2018Jefferies Financial GroupReiterated RatingBuy$195.00High
2/1/2018BarclaysBoost Price TargetOverweight ➝ Overweight$180.00 ➝ $200.00High
1/31/2018Maxim GroupReiterated RatingBuy$195.00Low
1/23/2018Bank of AmericaReiterated RatingBuy$180.00Low
1/9/2018JPMorgan Chase & Co.Reiterated RatingBuyLow
1/5/2018Bank of AmericaUpgradeNeutral ➝ Buy$180.00Low
1/4/2018OppenheimerBoost Price TargetOutperform$175.00 ➝ $190.00Low
12/12/2017Deutsche Bank AktiengesellschaftInitiated CoverageBuy$175.00High
12/11/2017CowenReiterated RatingBuy$200.00Low
10/27/2017Royal Bank of CanadaReiterated RatingBuyN/A
10/27/2017Needham & Company LLCReiterated RatingBuy$195.00N/A
10/27/2017Robert W. BairdReiterated RatingBuyN/A
10/26/2017HC WainwrightReiterated RatingHold$85.00N/A
10/26/2017Maxim GroupReiterated RatingBuy$195.00N/A
10/26/2017Piper Jaffray CompaniesReiterated RatingOverweight$205.00N/A
10/18/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$175.00 ➝ $181.00N/A
9/29/2017DA DavidsonInitiated CoverageBuy$200.00Low
9/29/2017BTIG ResearchInitiated CoverageBuy ➝ Buy$200.00Medium
9/27/2017BMO Capital MarketsReiterated RatingBuyLow
9/17/2017Needham & Company LLCReiterated RatingBuy$195.00Low
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$175.00Low
8/22/2017Jefferies Financial GroupReiterated RatingBuyHigh
8/1/2017CowenReiterated RatingBuyMedium
8/1/2017ArgusBoost Price TargetBuy$71.46 ➝ $175.00Low
7/27/2017BMO Capital MarketsReiterated RatingOutperform$180.00 ➝ $182.00Low
7/27/2017OppenheimerBoost Price TargetOutperform$150.00 ➝ $175.00Medium
7/27/2017JPMorgan Chase & Co.Set Price TargetBuy$175.00 ➝ $184.00High
7/27/2017Maxim GroupSet Price TargetBuy$195.00High
7/22/2017Morgan StanleyReiterated RatingOverweight$153.00 ➝ $190.00Low
7/21/2017Robert W. BairdReiterated RatingOutperform$136.00 ➝ $171.00Low
7/21/2017Needham & Company LLCReiterated RatingBuy$155.00 ➝ $195.00Low
7/21/2017BMO Capital MarketsReiterated RatingOutperform$132.00 ➝ $180.00Low
7/21/2017CitigroupReiterated RatingBuy$135.00 ➝ $190.00Low
7/19/2017JPMorgan Chase & Co.Set Price TargetBuy$129.00 ➝ $175.00Low
7/19/2017Maxim GroupSet Price TargetBuy$143.00 ➝ $195.00Low
7/19/2017UBS GroupDowngradeBuy ➝ Neutral$135.00 ➝ $174.00High
7/19/2017Credit Suisse GroupBoost Price TargetOutperform$125.00 ➝ $195.00High
7/19/2017JMP SecuritiesReiterated RatingOutperformHigh
7/19/2017Raymond JamesUpgradeMarket Perform ➝ Outperform$181.00High
7/19/2017Piper Jaffray CompaniesBoost Price TargetOverweight$194.00High
7/19/2017Jefferies Financial GroupReiterated RatingBuy$155.00 ➝ $185.00High
7/19/2017HC WainwrightReiterated RatingHold$85.00High
7/19/2017Janney Montgomery ScottUpgradeNeutral ➝ Buy$98.00High
7/19/2017CowenUpgradeMarket Perform ➝ Outperform$105.00 ➝ $200.00High
7/19/2017BarclaysUpgradeEqual Weight ➝ Overweight$115.00 ➝ $180.00High
7/18/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$130.00 ➝ $154.00High
7/10/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$155.00High
7/6/2017CowenReiterated RatingMarket Perform$105.00Low
6/23/2017Needham & Company LLCUpgradeHold ➝ Buy$155.00Medium
6/22/2017SVB LeerinkReiterated RatingOutperformMedium
6/9/2017Jefferies Financial GroupReiterated RatingBuy$126.00Low
6/2/2017CIBCUpgradeMarket Perform ➝ OutperformLow
6/2/2017OppenheimerUpgradeMarket Perform ➝ Outperform$150.00Medium
5/19/2017Maxim GroupSet Price TargetBuy$143.00Low
5/19/2017UBS GroupReiterated RatingBuy$132.00 ➝ $135.00N/A
5/19/2017JMP SecuritiesReiterated RatingOutperform$125.00 ➝ $127.00Low
5/19/2017Bank of AmericaReiterated RatingNeutral$121.00 ➝ $125.00Low
5/19/2017Morgan StanleyReiterated RatingOverweight$150.00 ➝ $153.00Low
5/2/2017Jefferies Financial GroupReiterated RatingBuy$126.00High
4/30/2017OppenheimerReiterated RatingHoldLow
4/28/2017Needham & Company LLCReiterated RatingHoldLow
4/28/2017Robert W. BairdBoost Price TargetOutperform$115.00 ➝ $136.00Low
4/28/2017Credit Suisse GroupBoost Price TargetOutperform$108.00 ➝ $125.00Low
4/28/2017Maxim GroupReiterated RatingBuy$143.00High
4/23/2017BarclaysReiterated RatingEqual Weight$90.00 ➝ $100.00Low
4/4/2017Credit Suisse GroupReiterated RatingHold$108.00Medium
4/2/2017HC WainwrightReiterated RatingNeutral$85.00Low
3/31/2017JMP SecuritiesReiterated RatingOutperform$115.00 ➝ $121.00Medium
3/31/2017Maxim GroupUpgradeHold ➝ Buy$143.00Low
3/30/2017CowenReiterated RatingMarket Perform$75.00Low
3/29/2017CitigroupBoost Price TargetBuy$105.00 ➝ $124.00Low
3/29/2017Robert W. BairdReiterated RatingOutperform$115.00Low
3/29/2017Credit Suisse GroupBoost Price TargetOutperform$100.00 ➝ $108.00Low
3/29/2017Stifel NicolausBoost Price TargetBuy$100.00 ➝ $129.00High
3/29/2017BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$89.67 ➝ $100.00High
3/29/2017Jefferies Financial GroupReiterated RatingBuy$100.00High
3/20/2017SVB LeerinkReiterated RatingOutperformMedium
3/17/2017JMP SecuritiesUpgradeMarket Perform ➝ Outperform$103.73 ➝ $115.00Low
3/14/2017ArgusReiterated RatingBuy$115.00 ➝ $92.95Low
3/9/2017UBS GroupInitiated CoverageBuy ➝ Buy$106.00N/A
3/7/2017BMO Capital MarketsReiterated RatingMarket Perform$78.00N/A
3/6/2017Robert W. BairdReiterated RatingOutperform$115.00N/A
3/1/2017CitigroupInitiated CoverageBuy ➝ Buy$105.00N/A
2/27/2017OppenheimerReiterated RatingHoldN/A
2/11/2017CowenSet Price TargetHold$75.00N/A
2/10/2017Robert W. BairdReiterated RatingOutperform ➝ PositiveN/A
2/3/2017Maxim GroupReiterated RatingHoldN/A
1/26/2017HC WainwrightSet Price TargetHold$85.00N/A
1/26/2017Maxim GroupReiterated RatingHoldN/A
1/26/2017CowenReiterated RatingHold$75.00N/A
1/26/2017Stifel NicolausLower Price TargetBuy$108.00 ➝ $100.00N/A
1/20/2017Needham & Company LLCReiterated RatingHoldN/A
1/17/2017Maxim GroupReiterated RatingHoldN/A
1/9/2017JMP SecuritiesDowngradeMarket PerformN/A
1/9/2017Robert W. BairdReiterated RatingBuy$115.00N/A
1/8/2017Jefferies Financial GroupReiterated RatingBuyN/A
1/3/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
12/25/2016Piper Jaffray CompaniesSet Price TargetBuy$129.00N/A
12/23/2016JMP SecuritiesReiterated RatingOutperform$103.00N/A
12/20/2016Credit Suisse GroupSet Price TargetBuy$100.00N/A
12/15/2016OppenheimerInitiated CoverageMarket PerformN/A
12/9/2016Jefferies Financial GroupReiterated RatingBuy$102.00N/A
12/7/2016Janney Montgomery ScottReiterated RatingNeutral$98.00N/A
11/30/2016Jefferies Financial GroupReiterated RatingBuy$102.00N/A
11/30/2016BMO Capital MarketsReiterated RatingMarket Perform$88.00N/A
11/29/2016Robert W. BairdReiterated RatingOutperform$115.00N/A
11/29/2016BarclaysDowngradeOverweight ➝ Equal Weight$100.00 ➝ $90.00N/A
11/17/2016Janney Montgomery ScottInitiated CoverageNeutral$98.00N/A
11/1/2016William BlairDowngradeOutperform ➝ Market Perform$105.00 ➝ $81.00N/A
10/28/2016Stifel NicolausReiterated RatingBuy$109.00 ➝ $108.00N/A
10/28/2016Jefferies Financial GroupReiterated RatingBuy$105.00 ➝ $102.00N/A
10/26/2016SVB LeerinkReiterated RatingOutperform$112.00 ➝ $111.00N/A
10/26/2016BMO Capital MarketsReiterated RatingMarket Perform$87.00 ➝ $88.00N/A
10/24/2016HC WainwrightDowngradeBuy ➝ Neutral$155.00 ➝ $85.00N/A
10/21/2016Jefferies Financial GroupReiterated RatingBuy$105.00N/A
10/12/2016Royal Bank of CanadaReiterated RatingBuyN/A
10/12/2016Jefferies Financial GroupReiterated RatingBuy$104.00N/A
10/5/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/A
10/1/2016Royal Bank of CanadaReiterated RatingBuyN/A
9/30/2016Jefferies Financial GroupReiterated RatingBuy$107.00 ➝ $104.00N/A
9/30/2016SVB LeerinkReiterated RatingOutperformN/A
9/30/2016Robert W. BairdReiterated RatingNeutral$128.00 ➝ $115.00N/A
9/29/2016Stifel NicolausSet Price TargetBuy$109.00N/A
9/29/2016Maxim GroupReiterated RatingHoldN/A
9/28/2016Credit Suisse GroupSet Price TargetBuy$110.00N/A
9/17/2016SVB LeerinkSet Price TargetBuy$112.00N/A
9/15/2016Jefferies Financial GroupReiterated RatingBuy$107.00N/A
9/15/2016BMO Capital MarketsReiterated RatingHold$87.00N/A
9/15/2016SVB LeerinkReiterated RatingOutperform$113.00N/A
9/15/2016Stifel NicolausBoost Price TargetBuy$105.00 ➝ $109.00N/A
9/13/2016CitigroupInitiated CoverageMarket PerformN/A
9/13/2016Raymond JamesInitiated CoverageMarket PerformN/A
8/16/2016Robert W. BairdReiterated RatingOutperform$128.00N/A
8/16/2016Jefferies Financial GroupReiterated RatingBuy$107.00N/A
8/16/2016Royal Bank of CanadaReiterated RatingBuyN/A
8/16/2016JMP SecuritiesReiterated RatingBuyN/A
8/16/2016Maxim GroupReiterated RatingHoldN/A
8/16/2016Stifel NicolausLower Price TargetBuy$108.00 ➝ $105.00N/A
8/15/2016SVB LeerinkReiterated RatingOutperform$113.00N/A
7/31/2016Jefferies Financial GroupReiterated RatingBuy$102.00 ➝ $107.00N/A
7/31/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
7/28/2016Maxim GroupReiterated RatingHoldN/A
7/28/2016CowenReiterated RatingHoldN/A
7/28/2016Morgan StanleyLower Price TargetOverweight$140.00 ➝ $139.00N/A
7/28/2016SVB LeerinkReiterated RatingOutperform$104.00 ➝ $113.00N/A
(Data available from 7/25/2016 forward)
Vertex Pharmaceuticals logo
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $200.50
Low: $195.50
High: $203.52

50 Day Range

MA: $201.76
Low: $187.49
High: $216.77

52 Week Range

Now: $200.50
Low: $185.32
High: $285.57


2,887,392 shs

Average Volume

2,182,994 shs

Market Capitalization

$51.90 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Vertex Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Vertex Pharmaceuticals in the last twelve months: Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Credit Suisse Group AG, Daiwa Capital Markets, Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Maxim Group, Morgan Stanley, Needham & Company LLC, Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist, Truist Securities, UBS Group AG, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for VRTX.

What is the current price target for Vertex Pharmaceuticals?

18 Wall Street analysts have set twelve-month price targets for Vertex Pharmaceuticals in the last year. Their average twelve-month price target is $264.44, suggesting a possible upside of 31.9%. Truist has the highest price target set, predicting VRTX will reach $331.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $170.00 for Vertex Pharmaceuticals in the next year.
View the latest price targets for VRTX.

What is the current consensus analyst rating for Vertex Pharmaceuticals?

Vertex Pharmaceuticals currently has 1 sell rating, 5 hold ratings and 17 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VRTX will outperform the market and that investors should add to their positions of Vertex Pharmaceuticals.
View the latest ratings for VRTX.

What other companies compete with Vertex Pharmaceuticals?

How do I contact Vertex Pharmaceuticals' investor relations team?

Vertex Pharmaceuticals' physical mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company's listed phone number is (617) 341-6100 and its investor relations email address is [email protected] The official website for Vertex Pharmaceuticals is